Regulatory Development
Zydus Receives US FDA Priority Review for Saroglitazar NDA in Primary Biliary Cholangitis Treatment
NSE
zyduslife
BSE
532321
Zydus Lifesciences Limited announced that the US Food and Drug Administration (US FDA) has granted Priority Review status to the New Drug Application (NDA) for saroglitazar. The proposed indication is for treatment of Primary Biliary Cholangitis (PBC) in adults with inadequate response or intolerance to ursodeoxycholic acid (UDCA). The US FDA has assigned a PDUFA target action date of November 27, 2026.
PRICE-SENSITIVE TRIGGER
Event: US FDA Grants Priority Review for Saroglitazar NDA
Type: Regulatory Development
Impact: Positive
Immediate Effect: The Priority Review designation accelerates the regulatory review timeline for saroglitazar in the US market and strengthens Zydus’ specialty and innovation-led product pipeline.
Key Metrics:
- PDUFA Target Action Date: November 27, 2026
- Drug Candidate: Saroglitazar
- Target Indication: Primary Biliary Cholangitis (PBC)
- Regulatory Status: US FDA Priority Review Granted
Highlight:
- Priority Review status indicates the US FDA considers the therapy potentially significant for unmet medical needs in PBC treatment.
What Happened ?
Zydus Lifesciences Limited informed exchanges that its wholly owned subsidiary, Zydus Therapeutics, received Priority Review designation from the US FDA for the New Drug Application (NDA) of saroglitazar.
The proposed indication is for treatment of Primary Biliary Cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have shown inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
The US FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 2026.
The development marks a significant regulatory milestone for Zydus’ innovation-led specialty drug pipeline and strengthens its positioning in liver and metabolic disease therapies.
Key Details
US FDA Regulatory Update:
- US FDA granted Priority Review to saroglitazar NDA.
- Application submitted through wholly owned subsidiary Zydus Therapeutics.
- Proposed indication targets Primary Biliary Cholangitis (PBC).
- Drug intended for use with UDCA in patients with inadequate response.
- Monotherapy usage proposed for patients intolerant to UDCA.
- US FDA assigned PDUFA action date of November 27, 2026.
- Priority Review shortens standard review timelines for potentially important therapies.
- Development supports Zydus’ innovation-focused specialty pharmaceutical strategy.
Note:
- Priority Review designation is typically granted to therapies that may offer meaningful improvement in treatment, diagnosis, or prevention of serious conditions.
Risk Analysis
Summary:
- While the Priority Review status improves regulatory visibility, final approval remains subject to US FDA review outcomes, clinical evaluation, and labeling decisions.
Key Risks:
- Priority Review does not guarantee final regulatory approval.
- Additional clinical, manufacturing, or safety-related queries may emerge during review.
- Commercial success will depend on physician adoption and competitive positioning.
- Regulatory timelines may still change depending on FDA review developments.
- Specialty liver disease markets remain highly regulated and clinically competitive.
Worst Case Scenario:
- If the US FDA issues a Complete Response Letter (CRL) or seeks additional clinical data, commercialization timelines and future revenue expectations could be delayed.
Risk Level: Medium
Company Commentary
- Zydus Therapeutics received Priority Review from the US FDA for saroglitazar NDA.
- Proposed indication includes treatment of PBC patients with inadequate response to UDCA.
- Saroglitazar may also be used as monotherapy in patients intolerant to UDCA.
- The US FDA assigned a PDUFA target action date of November 27, 2026.
- Management highlighted the advancement as part of the company’s innovation-led healthcare strategy.
Official Exchange Filing: Zydus Lifesciences Limited